PTPN2 treatment significantly reduces serum triglyceride, total cholesterol, and low-density lipoprotein-cholesterol levels, and also reduces metabolic disturbances and hyperglycemia in mice (Y. Li et al., 2019; Wiede et al., 2019). This evidence concerns the gene PTPN2 and Hyperglycemia.